Repligen Corp chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 14.46
Dividend & YieldN/A$ (N/A)
Beta 1.05
Market capitalization 9.3B
Operating cash flow 159.82M
ESG Scores unknown

Company description

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Sector: Healthcare - Industry: Medical Instruments & Supplies

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities 2.27M 662k 2.46M 19.52M
Total Cashflows From Investing Activities -14.04M -205.31M -201.38M -221.17M
Net Borrowings -11k 163.48M -21k -21k
Total Cash From Financing Activities 3.41M 484.87M 305.92M 961k
Change To Operating Activities -3.66M 13.2M -1.39M 14.65M
Issuance Of Stock 3.42M 321.88M 305.93M 3.88M
Net Income 16.62M 21.41M 59.93M 128.29M
Change In Cash 20.06M 343.58M 179.88M -113.48M
Effect Of Exchange Rate -2.08M -3.19M 12.73M -12.29M
Total Cash From Operating Activities 32.77M 67.22M 62.62M 119.02M
Depreciation 15.78M 20.87M 27.07M 38.45M
Change To Account Receivables -8.7M -5.68M -20.44M -46.52M
Other Cashflows From Financing Activities
Change To Netincome 10.26M 20.02M 14.02M 42.88M
Capital Expenditures -10.63M -18.5M -22.45M -67.09M

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development 15.82M 19.45M 20.18M 34.27M
Income Before Tax 21.44M 26.15M 59.22M 153.54M
Net Income 16.62M 21.41M 59.93M 128.29M
Selling General Administrative 65.69M 95.61M 115.42M 183.37M
Gross Profit 107.5M 152.63M 210.36M 400.78M
Ebit 25.99M 37.57M 74.76M 183.14M
Operating Income 25.99M 37.57M 74.76M 183.14M
Interest Expense -6.71M -9.29M -12.13M -12.71M
Income Tax Expense 4.82M 4.74M -709k 25.25M
Total Revenue 194.03M 270.25M 366.26M 670.53M
Cost Of Revenue 86.53M 117.62M 155.9M 269.75M
Total Other Income ExpenseNet -4.55M -11.41M -15.54M -29.6M
Net Income From Continuing Ops 16.62M 21.41M 59.93M 128.29M
Net Income Applicable To Common Shares 16.62M 21.41M 59.93M 128.29M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 159.05M 340.35M 373.74M 608.29M
Total Stockholder Equity 615.57M 1.06B 1.53B 1.75B
Other Current Liabilities 2.86M 10.38M 18.32M 21.55M
Total Assets 774.62M 1.4B 1.9B 2.36B
Common Stock 439k 521k 548k 553k
Other Current Assets 752k 13.19M 12.14M 12.38M
Retained Earnings -15.57M 5.84M 65.77M 194.06M
Treasury Stock -11.89M -15.03M 2.08M -16.89M
Cash 193.82M 528.39M 717.29M 603.81M
Total Current Liabilities 129.84M 48.31M 318.96M 375.26M
Other Stockholder Equity -11.89M -15.03M 2.08M -16.89M
Property, Plant, and Equipment 32.18M 74.16M 92.05M 226.52M
Total Current Assets 275.74M 641.83M 902.38M 931.68M
Net Tangible Assets 153.4M 378.8M 623.75M 552.43M
Net Receivables 35.75M 43.67M 71.39M 117.42M
Accounts Payable 10.49M 11.43M 16.88M 36.2M


Insider Transactions

Here are the insider transactions of stock shares related to Repligen Corp:

Filer Name Transaction Text Ownership Date Filer Relation Shares
HUNT ANTHONY JOHNSale at price 200.00 per share.D2022-11-11Chief Executive Officer25k
HUNT ANTHONY JOHNConversion of Exercise of derivative security at price 33.87 per share.D2022-11-11Chief Executive Officer25k
SNODGRES JONConversion of Exercise of derivative security at price 59.52 per share.D2022-10-07Chief Financial Officer466
DAWES KAREN ASale at price 227.17 per share.D2022-09-09Director775
HUNT ANTHONY JOHNSale at price 220.08 - 227.01 per share.D2022-09-08Chief Executive Officer26.4k
HUNT ANTHONY JOHNConversion of Exercise of derivative security at price 33.87 per share.D2022-09-08Chief Executive Officer10k
SNODGRES JONSale at price 252.70 - 253.16 per share.D2022-08-16Chief Financial Officer6.7k
SNODGRES JONConversion of Exercise of derivative security at price 86.10 - 215.58 per share.D2022-08-16Chief Financial Officer4.02k
KURIYEL RALFSale at price 254.14 - 255.20 per share.D2022-08-11Officer4.84k
KURIYEL RALFConversion of Exercise of derivative security at price 33.05 - 86.10 per share.D2022-08-11Officer4k
GEBSKI CHRISTINESale at price 243.01 per share.D2022-08-04Officer3.36k
BYLUND JAMESSale at price 240.40 per share.D2022-08-03Chief Operating Officer2k
BYLUND JAMESConversion of Exercise of derivative security at price 94.33 per share.D2022-08-03Chief Operating Officer2k
SNODGRES JONSale at price 220.00 per share.D2022-08-01Chief Financial Officer2k
HUNT ANTHONY JOHNSale at price 200.00 per share.D2022-07-21Chief Executive Officer24.8k
HUNT ANTHONY JOHNConversion of Exercise of derivative security at price 32.40 - 33.87 per share.D2022-07-21Chief Executive Officer20.15k
MUIR GLENN PStock Award(Grant) at price 0.00 per share.D2022-05-26Director534
DAWES KAREN AStock Award(Grant) at price 0.00 per share.D2022-05-26Director644
BARTHELEMY NICOLAS MStock Award(Grant) at price 0.00 per share.D2022-05-26Director534
EGLINTON MANNER CARRIEStock Award(Grant) at price 0.00 per share.D2022-05-26Director1.02k
MHATRE ROHINStock Award(Grant) at price 0.00 per share.D2022-05-26Director1.2k
KONSTANTINOV KONSTANTIN BStock Award(Grant) at price 0.00 per share.D2022-05-26Director534
DAWES KAREN ASale at price 149.18 - 152.84 per share.D2022-05-25Director14.71k
SNODGRES JONConversion of Exercise of derivative security at price 33.87 - 59.52 per share.D2022-03-08Chief Financial Officer4.17k
RYAN THOMAS F JRSale at price 197.58 - 198.48 per share.D2022-03-01Director2k
RYAN THOMAS F JRConversion of Exercise of derivative security at price 38.76 per share.D2022-03-01Director1k
HUNT ANTHONY JOHNStock Award(Grant) at price 0.00 per share.D2022-02-28Chief Executive Officer30.07k
SNODGRES JONStock Award(Grant) at price 0.00 per share.D2022-02-28Chief Financial Officer5.92k
KURIYEL RALFStock Award(Grant) at price 0.00 per share.D2022-02-28Officer4.23k
HUNT ANTHONY JOHNStock Award(Grant) at price 0.00 per share.D2022-02-24Chief Executive Officer15.86k
SNODGRES JONStock Award(Grant) at price 0.00 per share.D2022-02-24Chief Financial Officer3.44k
KURIYEL RALFStock Award(Grant) at price 0.00 per share.D2022-02-24Officer2.13k
BYLUND JAMESStock Award(Grant) at price 0.00 per share.D2022-02-24Chief Operating Officer3.37k
GEBSKI CHRISTINEStock Award(Grant) at price 0.00 per share.D2022-02-24Officer2.12k
SNODGRES JONStock Award(Grant) at price 0.00 per share.D2022-02-17Chief Financial Officer900
KURIYEL RALFStock Award(Grant) at price 0.00 per share.D2022-02-17Officer450
BYLUND JAMESStock Award(Grant) at price 0.00 per share.D2022-02-17Chief Operating Officer900
GEBSKI CHRISTINEStock Award(Grant) at price 0.00 per share.D2022-02-17Officer450
HUNT ANTHONY JOHNSale at price 273.91 - 281.40 per share.D2021-11-18Chief Executive Officer17.36k
HUNT ANTHONY JOHNConversion of Exercise of derivative security at price 32.40 per share.D2021-11-18Chief Executive Officer10k
DAWES KAREN ASale at price 259.75 - 271.28 per share.D2021-11-10Director4.78k
DAWES KAREN AConversion of Exercise of derivative security at price 26.12 per share.D2021-11-10Director4.78k
RYAN THOMAS F JRSale at price 288.00 - 302.00 per share.D2021-11-04Director2.29k
RYAN THOMAS F JRConversion of Exercise of derivative security at price 128.18 per share.D2021-11-02Director1.28k
DAWES KAREN ASale at price 299.02 - 306.49 per share.D2021-11-02Director2.4k
BARTHELEMY NICOLAS MSale at price 288.19 - 288.20 per share.D2021-10-29Director1.65k
BARTHELEMY NICOLAS MConversion of Exercise of derivative security at price 128.18 per share.D2021-10-29Director1.28k
DAWES KAREN ASale at price 290.02 - 295.82 per share.D2021-09-14Director274
HUNT ANTHONY JOHNSale at price 294.22 - 296.58 per share.D2021-09-09Chief Executive Officer25k
HUNT ANTHONY JOHNConversion of Exercise of derivative security at price 32.40 per share.D2021-09-09Chief Executive Officer25k
DAWES KAREN ASale at price 280.27 - 285.44 per share.D2021-09-01Director3.46k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Repligen Corp. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Repligen Corp

Here is the result of two systematic investment strategies applied to Repligen Corp. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Repligen Corp

The following chart shows the equity curve of the two systematic investment strategies applied to Repligen Corp:

Repligen Corp automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 298.39% on the backtest period.

Performance at glance

Performance

298.39 %

Latent gain

7021.42 $

Invested capital

2353.12 $

Annualized return

72.07 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Repligen Corp

This is the result of two momentum investment strategies applied to Repligen Corp. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Repligen Corp

The following chart shows all the entries opened by the momentum investment system on Repligen Corp:

Repligen Corp momentum entries
  • The first momentum investment strategy would give 356.39% of return on Repligen Corp. That represents 16155.57$ of latent gain with 4533.07$ of employed capital.
  • The second momentum investment strategy would give 352.76% of return on Repligen Corp. That represents 10578.21$ of latent gain with 2998.71$ of employed capital.
Performance at glance (1Q Momentum)

Performance

356.39 %

Latent gain

16155.57 $

Invested capital

4533.07 $

Annualized return

129.74 %
Performance at glance (2Q Momentum)

Performance

352.76 %

Latent gain

10578.21 $

Invested capital

2998.71 $

Annualized return

96.38 %

Momentum equity curve on Repligen Corp

The following chart shows the equity curve of the two momentum strategies applied to Repligen Corp:

Repligen Corp momentum equity

Note: the dividends potentially given by Repligen Corp are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Repligen Corp

The following chart shows the employed capital evolution of the two momentum strategies on Repligen Corp since the beginning:

Repligen Corp

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on Repligen Corp

Buy the dip entry openings on Repligen Corp

Repligen Corp

The performance achieved by the robo-advisor on Repligen Corp is 277.64%. That represents 712.98$ of latent gain with 256.8$ of employed capital. The following chart shows Repligen Corp stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Repligen Corp, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

277.64 %

Latent gain

712.98 $

Invested capital

256.8 $

Annualized return

129.74 %

Equity curve of the strategy applied to Repligen Corp

The following chart shows the result of the investment strategy applied to Repligen Corp:

Repligen Corp

Note: the dividends potentially given by Repligen Corp are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Repligen Corp

The following chart shows the employed capital evolution since the beginning of the investment strategy on Repligen Corp:

Repligen Corp

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Repligen Corp

In this section, I will compare the three previous investment strategies applied to Repligen Corp.

Equity curve comparison on Repligen Corp

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Repligen Corp investment strategy comparison

Employed capital comparison on Repligen Corp

Repligen Corp investment comparison

Performance comparison on Repligen Corp

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 298.39% 7021.42$ 2353.12$ 72.07%
Momentum 1 quarter 356.39% 16155.57$ 4533.07$ 91.38%
Momentum 2 quarters 352.76% 10578.21$ 2998.71$ 96.38%
Non-directional 277.64% 712.98$ 256.8$ 129.74%
Annualized return comparison

Automatic investment

72.07 %

Momentum 1Q

96.38 %

Momentum 2Q

96.38 %

Non-directional

129.74 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Repligen Corp:

Positive correlations

Most correlated stocks this year

  • Repligen Corp

  • Most correlated stocks last 3 months

  • Repligen Corp
  • PIMCO 15+ Year U.S. TIPS Index Exchange-Traded Fun
  • KINROSS GOLD CORP.

  • Negative correlation

    Most negatively correlated stocks this year


    Most negatively correlated stocks last 3 months

  • YAN TAT GROUP
  • LIFE CONCEPTS

  • Note: The algorithm computes the probability of correlation between Repligen Corp and the other stocks. There may be false positives or some missing correlated stocks. If the price of Repligen Corp does not vary for 36 weeks, the correlation calculation result will be wrong.


    Company information

    Company name Repligen Corp
    Country United States
    City Waltham
    Address Building 1
    Phone 781 250 0111
    Website www.repligen.com
    FullTime employees 1852
    Industry Medical Instruments & Supplies
    Sector Healthcare
    Exchange XNAS
    Ticker RGEN
    Market www.nasdaq.com

    Repligen Corp ESG Scores

    Environment scores

    Environment ESG Factors Scores
    Environment Score 0
    Peer Environment Performance unknown
    Environment Percentile unknown
    Palm Oil unknown
    Nuclear unknown
    Fur Leather unknown
    GMO unknown
    Coal unknown
    Pesticides unknown
    Animal Testing unknown

    Social scores

    Social ESG Factors Scores
    Social Score 0
    Peer Social Performance unknown
    Social Percentile unknown
    Highest Controversy unknown
    Peer Highest Controversy Performance unknown
    Adult unknown
    Gambling unknown
    Alcoholic unknown
    Tobacco unknown
    Catholic unknown
    Controversial Weapons unknown
    Small Arms unknown
    Military Contract unknown
    Peer Count unknown

    Related Controversy:


    Governance scores

    Governance ESG Factors Scores
    Governance Score 0
    Peer Governance Performance unknown
    Governance Percentile unknown

    ESG at glance
    Total ESG Scores: unknown
    Environment Score: 0
    Social Score: 0
    Governance Score: 0

    ESG Performance: unknown

    Peer Group: unknown

    Peer Esg Score Performance: unknown

    Rating Year: unknown

    Rating Month: unknown

    Max Age: unknown

    Percentile: unknown